Participated · Series A · Jul 2026

Wellumio develops a portable neuroimaging platform called Axana that uses patented PGFM (pulsed gradient–free mapping) technology to deliver rapid MRI-based stroke assessments at the point of care. The technology is designed to operate without contrast agents, cryogenics, or shielded rooms, enabling use in critical care settings. The company completed initial human feasibility trials and received a U.S. patent for its technology in December 2025. Wellumio is progressing toward regulatory approval and plans expanded clinical evaluation across additional sites and geographies. The company is led by co-founder and CEO Dr. Shieak Tzeng and is based in Wellington, New Zealand.

Participated · Seed · Jul 2026

Fluent is developing a low‑risk, minimally invasive brain–computer interface inserted beneath the scalp but outside the skull and positioned over the motor cortex to record activity related to speech muscles. The device’s signals are decoded and converted into text to enable faster communication for people with impaired speech from neurological conditions. Fluent has filed provisional patents and progressed through the Melbourne Entrepreneurial Centre’s TRAM Accelerator, and previously secured Proof of Concept funding. The company has raised over $2 million in its current pre-seed financing round from a mix of Australian and international investors. Fluent plans to begin human clinical trials later this year in Melbourne. Additional plans and operating metrics were not disclosed in the articles.

Participated · Seed · Nov 2025

Founded in 2022 by Cambridge-trained researchers Ben Woodington and Elise Jenkins, San Francisco–based Coherence Neuro decodes the body’s electrical patterns to understand and correct disease states. Its flagship device, SOMA-1, continually records neural activity and delivers precise stimulation, creating a bi-directional, closed-loop therapy that aims to nudge tumorous tissue back toward healthy function. Each deployed device feeds data into what the company calls the world’s largest disease-focused dataset, allowing the system to learn and improve with every patient. Coherence frames cancer as a system-level error rather than an external invader, seeking to replace aggressive treatments like surgery and chemotherapy with continuous, gentler neuromodulation. The company plans to begin first-in-human trials next year, using its newly secured capital to validate safety and efficacy. To date, it has raised a $10 million seed round to fund these efforts and further develop its data-driven platform.

Participated · Series A · Apr 2025

Phantom Neuro develops a minimally invasive neural interface platform called Phantom X to enable intuitive control of prosthetic limbs and robotic exoskeletons. Phantom X, originally developed at the Johns Hopkins University School of Medicine, is designed to restore natural movement by making assistive devices function as seamless extensions of the body. The company reported that its ASCENT study demonstrated 94% accuracy decoding real-time gestures across 11 essential hand and wrist movements. Phantom Neuro has received FDA Breakthrough Device and TAP designations for Phantom X, which may expedite regulatory approvals. The company plans to use new funding to accelerate preclinical testing, complete first-in-human trials, pursue regulatory submissions, and expand R&D for broader control applications beyond prosthetic limbs. Phantom Neuro is headquartered in Austin, Texas and has raised $28 million in total funding to date. Phantom Neuro develops a low-power, high-accuracy system intended to provide lifelike control of robotic orthopedic technologies. The company is positioned in the neurotech sector and is based in Austin, TX. Its core product targets control interfaces for robotic orthopedics, emphasizing low power consumption and high accuracy. The article does not disclose operating metrics such as revenue or user counts. Phantom Neuro announced a $6 million expanded seed financing, which increases its total funding to $9.5 million. The funding supports the company’s continued development of its control system for robotic orthopedic applications. Phantom Neuro is a neurotechnology company based in Austin, Texas and Baltimore, Maryland that is creating a system to enable lifelike control of robotic orthopedic technologies such as prosthetic limbs and exoskeletons. Its solution combines low-risk implantable sensors, AI, and enabling software to provide control of existing and next-generation orthopedic devices. The company is led by founder and CEO Dr. Connor Glass. Phantom Neuro raised seed funding to expand its operations and business reach. The $3.26M round was led by LionBird Ventures with participation from Draper Associates, Breakout Ventures, Blackrock Neurotech, Capital Factory, and private investors. As part of the financing, LionBird partner Robert Lord will join the board and LionBird Managing Partner Ed Michael will join as a board observer.